ArticlemBio2017
Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs.
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Accumulation of mutations in nsp4, E, and the S2 subunit underlies mammalian cell tropism expansion and virulence attenuation of avian coronavirus.PLoS pathogens · 2026Article
- Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza.Acta biomaterialia · 2026Article
- Lipoteichoic acid mediates binding ofmSphere · 2025Article
- Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus.Journal of virology · 2025Article
- SomaticiScience · 2025Article
- Fluorescent and bioluminescent bovine H5N1 influenza viruses for evaluation of antiviral interventions.Journal of virology · 2024Article
- Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA.Nature communications · 2024Article
- Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice.Vaccine: X · 2024Article
- Vaccines and cardiovascular outcomes: lessons learned from influenza epidemics.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Single-cell genome-wide association reveals that a nonsynonymous variant inCell genomics · 2022Article
- A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.Journal of virology · 2022Article
- Generation, Characterization, and Applications of Influenza A Reporter Viruses.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model.Vaccines · 2021Article
- ETV7 limits antiviral gene expression and control of influenza viruses.Science signaling · 2021Article
- IgA potentiates NETosis in response to viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses.iScience · 2021Article
- Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.Journal of virology · 2021Article
- Efforts to Improve the Seasonal Influenza Vaccine.Vaccines · 2020Article
- Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2020Review
- Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.Viruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Influenza virus vaccine production is currently limited by the ability to grow circulating human strains in chicken eggs or in cell culture. To facilitate cost-effective growth, vaccine strains are serially passaged under production conditions, which frequently results in mutations of the major antigenic protein, the viral hemagglutinin (HA). Human vaccination with an antigenically drifted strain is known to contribute to poor vaccine efficacy. To address this problem, we developed a replication-competent influenza A virus (IAV) with an artificial genomic organization that allowed the incorporation of two independent and functional HA proteins with different growth requirements onto the same virion. Vaccination with these viruses induced protective immunity against both strains from which the HA proteins were derived, and the magnitude of the response was as high as or higher than vaccination with either of the monovalent parental strains alone. Dual-HA viruses also displayed remarkable antigenic stability; even when using an HA protein known to be highly unstable during growth in eggs, we observed high-titer virus amplification without a single adaptive mutation. Thus, the viral genomic design described in this work can be used to grow influenza virus vaccines to high titers without introducing antigenic mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.